The University of North Carolina at Chapel Hill (UNC), in collaboration with Duke University and the Hamner Institute for Drug Safety Sciences, is well positioned for a T32 training program in clinical pharmacology. We have an outstanding research environment in clinical pharmacology with world-class programs in pharmacogenomics, drug discovery, drug development and drug safety, an outstanding track record of training clinician-scientists in clinical pharmacology, and an excellent applicant pool. The clinical pharmacology training program detailed in this application offers strong leadership, internationally-recognized mentors from multiple disciplines who are actively involved in clinical pharmacology, a wide-array of cutting edge technologies and resources, and a uniquely collaborative environment with strong institutional support. The national applicant pool for this program will be derived primarily from MDs in medical specialty training programs seeking a career path in clinical pharmacology. Trainees, guided by individualized mentoring teams, will complete clinical pharmacology coursework and engage in program-specific activities to gain expertise in all aspects of contemporary clinical pharmacology research, from ethics and pharmacogenomics to clinical trial design. Faculty mentors were chosen based on their productivity in clinical pharmacology research in at least one of four focus areas that form the core of this training program: Drug Disposition and Action;Pharmacogenomics;Drug-induced Organ Toxicity;Quantitative Pharmacology and Clinical Trial Design. A unique feature of this training program is the opportunity to focus on understudied areas in clinical pharmacology, specifically pediatrics and drug safety. The keen interest in clinical pharmacology within our potential trainee pool, the unparalleled investment in clinical pharmacology research resources at UNC, Duke University, and the Hamner-UNC Institute for Drug Safety Sciences, the intellectually-rich regional environment represented by Research Triangle Park with its concentration of biomedical sciences related to clinical pharmacology, and our longstanding excellent research and training infrastructure combine to create a moment of unsurpassed opportunity for training in clinical pharmacology.

Public Health Relevance

There has been an explosion in understanding of the biology underlying disease and interindividual variation in response to pharmacotherapy. This has provided unprecedented opportunities in drug development and the individualization of therapy to treat and ultimately cure disease. The proposed program will produce clinical pharmacologists that will be well-trained to lead the effort to capitalize on these great opportunities.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Institutional National Research Service Award (T32)
Project #
5T32GM086330-04
Application #
8685998
Study Section
Special Emphasis Panel (ZGM1)
Program Officer
Okita, Richard T
Project Start
2011-07-01
Project End
2016-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
4
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Cottrell, Mackenzie L; Prince, Heather M A; Allmon, Andrew et al. (2016) Cervicovaginal and Rectal Fluid as a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial Design. J Acquir Immune Defic Syndr 72:498-506
Parikh, Kishan S; Greiner, Melissa A; Suzuki, Takeki et al. (2016) Resting Heart Rate and Long-term Outcomes Among the African American Population: Insights From the Jackson Heart Study. JAMA Cardiol :
Garber, Adam M; Mentz, Robert J; Al-Khalidi, Hussein R et al. (2016) Clinical predictors and outcomes of patients with left ventricular thrombus following ST-segment elevation myocardial infarction. J Thromb Thrombolysis 41:365-73
Parikh, Kishan S; Rajagopal, Sudarshan; Fortin, Terry et al. (2016) Safety and Tolerability of High-dose Inhaled Treprostinil in Pulmonary Hypertension. J Cardiovasc Pharmacol 67:322-5
Chen, Yao; Zane, Nicole R; Thakker, Dhiren R et al. (2016) Quantification of Flavin-containing Monooxygenases 1, 3, and 5 in Human Liver Microsomes by UPLC-MRM-Based Targeted Quantitative Proteomics and Its Application to the Study of Ontogeny. Drug Metab Dispos 44:975-83
Duran, Charity G; Burbank, Allison J; Mills, Katherine H et al. (2016) A proof-of-concept clinical study examining the NRF2 activator sulforaphane against neutrophilic airway inflammation. Respir Res 17:89
Parikh, Kishan S; Coles, Adrian; Schulte, Phillip J et al. (2016) Relation of Angina Pectoris to Outcomes, Quality of Life, and Response to Exercise Training in Patients With Chronic Heart Failure (from HF-ACTION). Am J Cardiol 118:1211-1216
Onufrak, Nikolas J; Forrest, Alan; Gonzalez, Daniel (2016) Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing. Clin Ther 38:1930-47
Church, Rachel J; Otieno, Monicah; McDuffie, James Eric et al. (2016) Beyond miR-122: Identification of MicroRNA Alterations in Blood During a Time Course of Hepatobiliary Injury and Biliary Hyperplasia in Rats. Toxicol Sci 150:3-14
Autmizguine, Julie; Hornik, Christoph P; Benjamin Jr, Daniel K et al. (2016) Pharmacokinetics and Safety of Micafungin in Infants Supported With Extracorporeal Membrane Oxygenation. Pediatr Infect Dis J 35:1204-1210

Showing the most recent 10 out of 100 publications